Johnson & Johnson (NYSE:JNJ) is Roberts Glore & Co. Inc. IL's 6th Largest Position

Key Points

• Roberts Glore & Co. Inc. IL has reduced its holdings in Johnson & Johnson by 2.8%, selling 1,659 shares, which now represents 2.9% of their investment portfolio worth approximately $9.38 million.
• Several major institutional investors have increased their positions in Johnson & Johnson, with Vanguard Group Inc. owning over $38.8 billion in shares after growing its position by 0.5%.
• Johnson & Johnson's latest earnings report revealed $2.77 EPS, exceeding expectations, and the company announced a quarterly dividend of $1.30 per share, set to be paid on September 9th.

Roberts Glore & Co. Inc. IL cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 56,557 shares of the company's stock after selling 1,659 shares during the period. Johnson & Johnson accounts for about 2.9% of Roberts Glore & Co. Inc. IL's investment portfolio, making the stock its 6th biggest holding. Roberts Glore & Co. Inc. IL's holdings in Johnson & Johnson were worth $9,379,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the 4th quarter valued at $36,000. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the first quarter worth about $49,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.5%

Shares of JNJ stock traded up $0.82 during trading hours on Thursday, hitting $171.41. 9,314,579 shares of the company were exchanged, compared to its average volume of 9,367,092. The firm has a market cap of $412.81 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.17 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $172.18. The company has a 50 day simple moving average of $158.89 and a two-hundred day simple moving average of $157.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm posted $2.82 EPS. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Morgan Stanley increased their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.